Moderna, Pfizer and COVID-19

Now that Novavax has been added to the revamped COVID vaccines, you'll want to make sure to check on the changes to cost and ...
Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...
A small study on Covid vaccine safety has sparked an online tempest — and highlighted the conundrum faced by some scientists.
Effectiveness of 2024-25 COVID-19 vaccination against a COVID-19–associated ED/UC visit was 33% (95% confidence interval [CI] ...
US health officials are reevaluating a $590 million contract for bird flu shots that the Biden administration awarded to ...
COVID-19 vaccines target emerging variants, offering improved protection. Learn about their effectiveness, timing, and safety ...
It has been five years since the World Health Organisation (WHO) declared COVID-19 a pandemic in March 2020 a decision that ...
For now, Moderna may be a good stock to put on a watch list, but it's likely too risky and volatile for the vast majority of ...
The pandemic's volatility affected all public companies, but some saw their business deeply transformed. Here's how three of ...